CompletedNCT03866460
Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children
Studying Retinoblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Mary Elizabeth Davis, MSN, RN, AOCNSMemorial Sloan Kettering Cancer Center
- Intervention
- Distortion product otoacoustic emission measurement (DPOAE)(diagnostic_test)
- Enrollment
- 30 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2024
Study locations (1)
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03866460 on ClinicalTrials.govOther trials for Retinoblastoma
Additional recruiting or active studies for the same condition.